GlobeNewswire

Phase 2/Phase 3 Program - Cumulative Safety & Tolerability (Completed Studies)

Phase 2/Phase 3 Program - Cumulative Safety & Tolerability (Completed Studies)

Overview of Adverse Events and Discontinuations
Esperion Therapeutics, Inc.
Format

PNG

Source

Esperion Therapeutics, Inc.

Downloads